BioPacific Conference 2009 Agenda
Theme: Challenges and Opportunities in the U.S. and China: Through the Global Downturn and Beyond
Plenary Session: Successes, Challenges and
Opportunities of the Biotech Industry
-
Norbert Bischofberger, Ph.D. (Executive Vice President & Chief
Scientific Officer, Gilead Sciences): “Gilead Sciences: The Evolution
of HIV Treatment and Gilead’s Contributions” -
Nancy Chang, Ph.D. (Chairman and Managing Director, Caduceus Asia
partner Fund, OrbiMed Venture; Founder of Tanox): “Changing Nature of
Pharma R&D and Outsourcing Environment in Asia” -
Karl Sanford, Ph.D. (Vice President Technology, Genencor): “Recent
Developments in Industrial Biotechnology: From Industrial Enzymes to
Biochemicals to Biofuels”
Scientific Session: Advances in Oncology and
Neuroscience R&D
-
Ira Mellman, Ph.D. (Vice President, Research Oncology, Genentech):
“Oncology Research at Genentech: Where Basic Science Needs No
Translation” -
Peter Lamb, Ph.D. (Chief Scientific Officer, Exelixis): “Discovery
and Development of Targeted Small Molecule Therapeutics for Oncology” -
Professor Dean Felsher (Stanford University): “Reversing Cancer
through Targeted Oncogene Inactivation” -
Alexander “Sasha” Kamb, Ph.D. (Neuroscience Therapeutic Area Head,
Amgen): “Problems and (Possible) Solutions in the Neurosciences
Therapeutic Area”
Session on China Biotechnology and Drug Development
-
Joseph McCracken, Ph.D. (Vice President, Business Development,
Genentech): “Collaboration: a key to Genentech’s success as the
leading biotechnology company” -
Wayne Li, Ph.D. (Morningside Group): “The State and Future of
Biotech Funding in China” -
Jing-shan Hu, Ph.D. (Director, Licensing, Merck): “Maintaining a
Competitive Edge in a Changing Landscape” -
Jintao Zhang, Ph.D. (President, Shanghai Medicilon): “The CRO
Business in China Today and Tomorrow” -
Tony Zhang, Ph.D. (Managing Director and site head, China R&D, Eli
Lilly): “Pharmaceutical R&D Networks and NME Development Efficiency” -
Yingfei Wei, Ph.D. (Chief Scientific Officer, 3SBio): “Biosimilars
in China: Current State and Future” -
Allan Riting Liu, Ph.D. (Shanghai Fosun Pharmaceutical Group):
“Fosun Pharma and Its Licensing and R&D Alliance Strategy”
Expert Forum & Panel Discussion on Trends in Biotechnology
and Entrepreneurship
-
Mini Keynote: Brian Cunningham, J.D. (Senior Counsel and Co-Chair
of the Life Science Group, Morrison & Foerster): “Perspective on
Today’s BioPharmaceutical Environment” -
Distinguished Panelists: Jin-Long Chen, Ph.D. (CEO, NGM Biopharmaceuticals); Cheni Kwok, Ph.D.
(Senior Vice President, Poniard
Pharmaceuticals); Larry Wang, Ph.D. (President, GenScript); Alex Wu, Ph.D. (CEO,
Crown BioScience)
Major Sponsors’ Presentations:
-
Taicang Science Park
-
Zhangjiang Biotech & Pharma Base
-
GenScript
-
AzoPharma
-
Pharmaron